Cairo: Egyptian Drug Authority (EDA) Chairman Ali El-Ghamrawy met with a delegation from state-owned vaccine company VACSERA to discuss technical and regulatory issues related to the company's product submissions, a Cabinet statement said.According to State Information Service Egypt, discussions focused on enhancing cooperation, with the authority committed to providing technical support for products to meet local and international standards. This will boost local vaccine production and access new export markets.The meeting also addressed recent challenges faced by VACSERA and explored potential mechanisms to overcome them, in line with regulatory frameworks and without compromising product safety and security.In his remarks, El-Ghamrawy reiterated EDA's support for companies and its commitment to creating a regulatory environment that promotes quality, safety, efficiency, and transparency in Egypt's pharmaceutical industry.He further emphasised the authority's support for the localisation of pharmace utical manufacturing to enhance the domestic market and guarantee access to high-quality, cost-effective medications for patients.El-Ghamrawy emphasised the need to work with local pharmaceutical companies to enhance the localisation process. He also highlighted the Egyptian government's support in registering innovative medicines and addressing challenges for local pharmaceutical manufacturing.
EDA Chairman Engages with VACSERA Delegation on Vaccine Production
POPULAR POSTS
Nile Ship for Arab Youth to Foster Cultural Exchange Among 12 Nations
September 23, 2026
Egypt Prioritizes Education System Development, Says Minister
September 23, 2026
Egypt Eases Consular Access for Elderly and Disabled Citizens
September 23, 2026
Egypt and ICARDA Discuss Enhancement of Agricultural Research Collaboration
September 23, 2026
Health Minister Discusses Strategy to Expand Kidney Donor Database
September 20, 2026
Egypt Discusses Enhancing Media Coordination on Water Issues
September 20, 2026
Health Minister and World Bank Explore Future Health Sector Collaborations
September 20, 2026